Abstract:Apelin-36 was discovered as the endogenous ligand for the previously orphan receptor APJ. Apelin-36 has been linked to two major types of biological activities: cardiovascular (stimulation of cardiac contractility and suppression of blood pressure) and metabolic (improving glucose homeostasis and lowering body weight). It has been assumed that both of these activities are modulated through APJ. Here, we demonstrate that the metabolic activity of apelin-36 can be separated from canonical APJ activation. We developed a series of apelin-36 variants in which evolutionarily conserved residues were mutated, and evaluated their ability to modulate glucose homeostasis and body weight in chronic mouse models. We found that apelin-36(L28A) retains full metabolic activity, but is 100-fold impaired in its ability to activate APJ. In contrast to its full metabolic activity, apelin-36(L28A) lost the ability to suppress blood pressure in spontaneously hypertensive rats (SHR). We took advantage of these findings to develop a longer-acting variant of apelin-36 that could modulate glucose homeostasis without impacting blood pressure (or activating APJ). Apelin-36-[L28C(30kDa-PEG)] is 10,000-fold less potent than apelin-36 at activating the APJ receptor but retains its ability to significantly lower blood glucose and improve glucose tolerance in diet-induced obese mice. Apelin-36-[L28C(30kDa-PEG)] provides a starting point for the development of diabetes therapeutics that are devoid of the blood pressure effects associated with canonical APJ activation.

The apelin/APJ system as a therapeutic target in metabolic diseases

Apelin/APJ system as a therapeutic target in diabetes and its complications.

Apelin/APJ System As a Therapeutic Target in Diabetes and Its Complications

Apelin/APJ System: A Potential Therapeutic Target for Endothelial Dysfunction‐related Diseases

Apelin/APJ System: A Novel Promising Therapy Target for Pathological Angiogenesis

Targeting Drugs To Apj Receptor: From Signaling To Pathophysiological Effects

Apelin/APJ System: a Novel Promising Therapy Target for Thrombotic Diseases.

Apelin and APJ, a Novel Critical Factor and Therapeutic Target for Atherosclerosis.

Apelin/APJ: Vascular Function Regulatory Factor and New Targets for Drug Treatment

Apelin/APJ system: a promising therapy target for hypertension

Apelin-36 Modulates Blood Glucose and Body Weight Independently of Canonical APJ Receptor Signaling

Apelin/APJ System: A Bifunctional Target for Cardiac Hypertrophy

Targeting Drugs to Apj Receptor: the Prospect of Treatment of Hypertension and Other Cardiovascular Diseases

Apelin/APJ system: an emerging therapeutic target for neurological diseases

Apelin C-Terminal Fragments: Biological Properties and Therapeutic Potential

Apelin/APJ System: A Novel Therapeutic Target for Oxidative Stress-Related Inflammatory Diseases (Review)

Adipokine apelin and diabetes

Therapeutic potential of apelin and Elabela in cardiovascular disease

Regulatory function of apelin/APJ system on multiple systems

Apelin/APJ system: an emerging therapeutic target for respiratory diseases

Apelin receptor dimer: Classification, future prospects, and pathophysiological perspectives